Attached files
file | filename |
---|---|
8-K - China Botanic Pharmaceutical | v206306_8k.htm |
Company
Contact:
|
CCG
Investor Relations:
|
China
Botanic Pharmaceutical Inc.
|
Mr.
Mark Collinson, Partner
|
Ms. Portia Tan, IR
Contact
|
Phone:
+1-310-954-1343 (Los Angeles)
|
Tel:
86-451-8260-2162
|
Email:
mark.collinson@ccgir.com
|
Email:
ir@renhuang.com
|
Website:
www.ccgirasia.com
|
Mr. Crocker Coulson, President | |
ePhone: +1-646-213-1915 (New York) | |
Email: crocker.coulson@ccgir.com |
For
Immediate Release
China
Botanic Appoints David Dong as New Chief Financial Officer
HARBIN, CHINA – December
16,
2010 – China Botanic Pharmaceutical Inc. (AMEX: CBP) ("China Botanic" or
the "Company"), a developer, manufacturer and distributor of botanical products,
bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced
that Mr. David Dong was named the Company's new Chief Financial Officer (“CFO”)
on December
14, 2010.
Mr.
Dong's career spans over 10 years with key positions in finance, audit,
investment advisory and tax planning. From 2000-2010, Mr. Dong worked as an
investment manager with money management firms. Most recently, he was
an investment manager with Hatitac Inc., where he was responsible for funds and
stock investments and was involved in financial planning, risk management, tax
planning and accounting services. He also served as an advisor to
publicly and privately held institutional clients. From 1998 to 2000,
he worked as a senior audit manager with TianHua Accounting firm. He also spent
five years at Tsinghua Unisplendour Co., Ltd. where he progressed from sales
engineer to finance manager and was responsible for financial reporting,
budgeting, general accounting, credit and collateral and procurement-related
activities. He also assisted with corporate restructuring, including
relocation of Internal Audit, Tax, General Accounting, and Finance Departments
to improve communication and efficiency. Mr. Dong holds a Bachelor of
Engineering from North-Western Polytechnic University in China and is a
Certified Financial Planner in Canada.
Mr.
Shaoming Li, Chairman and Chief Executive Officer of China Botanic, stated, “Mr.
Dong brings a wealth of experience and knowledge to China Botanic. I
am confident that his knowledge about capital markets will be valuable as we
grow our business and expand our capabilities through targeted acquisitions.
“
“I am
excited by the opportunity to join a company with an attractive revenue growth
and profitability track record," said Mr. Dong. "I look forward to assisting the
Company in managing its financial goals and enhancing communication with
shareholders to achieve long-term growth in shareholder value.”
ABOUT
CHINA BOTANIC PHARMACEUTICAL INC.
China
Botanic Pharmaceutical Inc. is engaged in the research, development,
manufacturing, and distribution of botanical products, bio-pharmaceutical
products, and traditional Chinese medicines ("TCM"), in the People's Republic of
China. All of the Company's products are produced at its three
GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The
Company distributes its botanical anti-depression and nerve-regulation products,
biopharmaceutical products, and botanical antibiotic and OTC TCMs through its
network of over 3,000 distributors and over 70 sales centers across 24 provinces
in China.
Safe
Harbor Statement
This
press release contains certain statements that may include forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements are based upon management’s beliefs, assumptions and
expectations of the Company’s future operations and economic performance, taking
into account the information currently available to management. These statements
are not statements of historical fact. Forward-looking statements involve risks
and uncertainties, some of which are not currently known that may cause actual
results, performance or financial condition to be materially different from the
expectations of future results, performance or financial condition expressed or
implied in any forward-looking statements. These forward-looking statements are
based on current plans and expectations and are subject to a number of
uncertainties including, but not limited to the Company’s ability to manage
expansion of its operations effectively, and other factors detailed in the
Company’s annual report on Form 10-K and other filings with the Securities and
Exchange Commission. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. You are cautioned not to unduly rely on
such forward-looking statements when evaluating the information presented
herein.
###